Literature DB >> 11597808

Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation.

P J Schlembach1, T A Buchholz, M I Ross, S M Kirsner, G J Salas, E A Strom, M D McNeese, G H Perkins, K K Hunt.   

Abstract

PURPOSE: To evaluate the volume of nodal irradiation associated with breast-conserving therapy, we defined the anatomic relationship of sentinel lymph nodes and axillary level I and II lymph nodes in patients receiving tangential breast irradiation. METHODS AND MATERIALS: A retrospective analysis of 65 simulation fields in women with breast cancer treated with sentinel lymph node surgery and 39 women in whom radiopaque clips demarcated the extent of axillary lymph node dissection was performed. We measured the relationship of the surgical clips to the anatomic landmarks and calculated the percentage of prescribed dose delivered to the sentinel lymph node region.
RESULTS: A cranial field edge 2.0 cm below the humeral head the sentinel lymph node region was included or at the field edge in 95% of the cases and the entire extent of axillary I and II dissection in 43% of the axillary dissection cases. In the remaining 57%, this field border encompassed an average of 80% of cranial/caudal extent of axillary level I and II dissection. In 98.5% of the cases, all sentinel lymph nodes were anterior to the deep field edge and 71% were anterior to the chest wall-interface, whereas 61% of the axillary dissection cohort had extension deep to the chest wall-lung interface. If the deep field edge had been set 2 cm below the chest wall-lung interface, the entire axillary dissection would have been included in 82% of the cases, and the entire sentinel lymph node would have been covered with a 0.5-cm margin. The median dose to the sentinel lymph node region was 98% of the prescribed dose.
CONCLUSIONS: By extending the cranial border to 2 cm below the humeral head and 2 cm deep to the chest wall-lung interface, the radiotherapy fields used to treat the breast can include the sentinel lymph node region and most of axillary levels I and II.

Entities:  

Mesh:

Year:  2001        PMID: 11597808     DOI: 10.1016/s0360-3016(01)01684-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.

Authors:  Elizabeth A Mittendorf; Kelly K Hunt; Judy C Boughey; Roland Bassett; Amy C Degnim; Robyn Harrell; Min Yi; Funda Meric-Bernstam; Merrick I Ross; Gildy V Babiera; Henry M Kuerer; Rosa F Hwang
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

2.  Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer.

Authors:  Allan W Silberman; Carie McVay; Jason S Cohen; Jack F Altura; Sandra Brackert; Gregory P Sarna; Daphne Palmer; Albert Ko; Leslie Memsic
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

3.  Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy.

Authors:  G Alço; S I Iğdem; T Ercan; M Dinçer; R Sentürk; S Atilla; F Oral Zengin; S Okkan
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

Review 4.  Radiotherapy of the Lymphatic Pathways in Early Breast Cancer.

Authors:  Marie-Luise Sautter-Bihl; Felix Sedlmayer
Journal:  Breast Care (Basel)       Date:  2015-08-19       Impact factor: 2.860

5.  Optimal management of sentinel lymph node positive biopsy patients in early breast cancer.

Authors:  Geraldine M Jacobson; Jessica F Partin; Mohamad A Salkeni
Journal:  Ann Transl Med       Date:  2015-05

Review 6.  Consensus on the regional lymph nodes irradiation in breast cancer.

Authors:  E Bayo; I Herruzo; M Arenas; M Algara
Journal:  Clin Transl Oncol       Date:  2013-03-22       Impact factor: 3.405

7.  Radiation field design in the ACOSOG Z0011 (Alliance) Trial.

Authors:  Reshma Jagsi; Manjeet Chadha; Janaki Moni; Karla Ballman; Fran Laurie; Thomas A Buchholz; Armando Giuliano; Bruce G Haffty
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

8.  DEGRO practical guidelines: radiotherapy of breast cancer III--radiotherapy of the lymphatic pathways.

Authors:  M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; C Fussl; W Haase; W Harms; M D Piroth; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-03-05       Impact factor: 3.621

9.  How nescience may obscure evidence.

Authors:  M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; M D Piroth; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-10       Impact factor: 3.621

Review 10.  Management of Axilla in 2015 in Indian Scenario.

Authors:  D K Vijaykumar; M Arunlal
Journal:  Indian J Surg Oncol       Date:  2015-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.